How tRNAs Could Revolutionize Treatment for Dravet & More

In this short clip from our BIO 2025 interview with him, Tevard Biosciences CEO Daniel Fischer explains tRNA-based suppression of premature stop codons—mutations that account for about 25% of Dravet cases and up to 20% of other genetic diseases. This suppressor tRNA platform is disease-agnostic, allowing for the same construct to potentially treat multiple conditions, including Duchenne muscular dystrophy and dilated cardiomyopathy.

Access our full interview with Fischer here!